SCHEMBL25317242

SCHEMBL25317242

C=CCOc1cc(C)cc(OC)c1OCC=C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.50
PTGS1 P23219 3/20 0.49
PTGS2 P35354 3/20 0.49
HSD17B10 Q99714 1/20 0.48
KDM4E B2RXH2 1/20 0.43
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 1/20 0.43
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SYK P43405 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
PDE4B Q07343 1/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17655666 0.88 ACHE (0.48) ACHEPTGS1PTGS2HSD17B10KDM4E
SCHEMBL8542113 0.79 KDM4E (0.55) PTGS1PTGS2HSD17B10KDM4EMAPT
SCHEMBL14363097 0.79 ACHE (0.59) ACHEHSD17B10KDM4ENPSR1MAPT
SCHEMBL20970915 0.78 HTR2A (0.66) PTGS1PTGS2HSD17B10KDM4ELMNA
SCHEMBL9709192 0.77 HSD17B10 (0.50) PTGS1PTGS2HSD17B10LMNANPSR1
SCHEMBL7457596 0.77 HSD17B10 (0.54) PTGS1PTGS2HSD17B10KDM4EMAPT
SCHEMBL9709129 0.77 HSD17B10 (0.50) PTGS1PTGS2HSD17B10LMNANPSR1
SCHEMBL8547102 0.77 KDM4E (0.52) PTGS1PTGS2HSD17B10KDM4ESMN1; SMN2
SCHEMBL17655655 0.77 PTGS1 (0.40) ACHEPTGS1PTGS2HSD17B10KDM4E
SCHEMBL22215821 0.76 SMN1; SMN2 (0.55) HSD17B10KDM4ELMNAMGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059153-A1 BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS IC-MedTech Corp. 2025-02-20 US disclosed
EP-4465981-A1 BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS IC-Medtech Corp. (US) 2024-11-27 EP disclosed
CN-118891036-A Bicyclic quinones, pharmaceutical compositions and therapeutic uses IC医药科技公司 2024-11-01 CN disclosed
WO-2023141410-A1 BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS IC-MedTech Corp. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059153-A1 BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS SDHA, NQO1, NDUFA7 ACHE 328/4885PTGS1 344/4885PTGS2 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.